Last reviewed · How we verify
NCT03642158
rTMS for Cognitive Rehabilitation After TBI
NA trial testing repetitive Transcranial Magnetic Stimulation in Cognitive Impairment in 34 participants. Completed in 30 November 2020.
30 November 2020
Quick facts
| Lead sponsor | Hunter Holmes Mcguire Veteran Affairs Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | health services research |
| Enrollment | 34 |
| Start date | 1 December 2017 |
| Primary completion | 30 November 2020 |
| Estimated completion | 30 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- repetitive Transcranial Magnetic Stimulation
Conditions studied
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Traumatic Brain Injury — all drugs for Traumatic Brain Injury →
Sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Who can join
Adults 18 to 65, any sex, with Cognitive Impairment or Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A novel and promising therapy for cognitive dysfunction is non-invasive brain stimulation, of which transcranial magnetic stimulation (TMS) is a form. TMS is currently FDA-approved for use in depression and migraine. It is under investigation for use in a number of other neurologic and psychiatric disorders. In addition to its potential to improve affective symptoms, recent research has suggested that TMS targeted to select cortical regions can also improve cognition. In trials of TMS therapy for psychiatric disorders, several studies have shown benefits for cognitive function alongside symptom amelioration. In healthy persons, a course of stimulation of the parietal area improved objective measures of learning and memory. Among persons with TBI, there have been case reports supporting improvement in cognitive function and postconcussive symptoms; however, there have not yet been any controlled studies of TMS for TBI-related cognitive dysfunction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03642158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of repetitive Transcranial Magnetic Stimulation
Trials testing the same drug.
- NCT07173920 — Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localizat · NA · recruiting
- NCT07058584 — Synergistic Effects of Aerobic Exercise and Repetitive Transcranial Magnetic Stimulation · NA · active not recruiting
- NCT06152705 — Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression · NA · recruiting
- NCT05467657 — Transcranial Magnetic Stimulation on Somtosensory Cortex Enhances Motor Learning in People With Stroke · NA · completed
- NCT05535062 — Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature · NA · completed
Other recruiting trials for Cognitive Impairment
Currently open trials in the same condition.
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
Other Hunter Holmes Mcguire Veteran Affairs Medical Center trials
Trials by the same sponsor.
- NCT06464952 — Microbiome Modulation With Prebiotics in PTSD and Cirrhosis · NA · recruiting
- NCT06052176 — Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement · Phase 2 · recruiting
- NCT06052150 — Oral Health In Cirrhosis of the Liver (ORACLE) · active not recruiting
- NCT06110364 — Vagal Nerve Stimulation as an Alternative Therapy for Premature Ventricular Contractions · Phase 3 · withdrawn
- NCT05604274 — Longitudinal Monitoring of Stool Characteristics · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03642158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunter Holmes Mcguire Veteran Affairs Medical Center
- Last refreshed: 9 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing